Roger Song
Stock Analyst at Jefferies
(4.29)
# 349
Out of 5,170 analysts
55
Total ratings
50%
Success rate
20.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Buy | $8 → $16 | $4.83 | +231.26% | 4 | Mar 18, 2026 | |
| MANE Veradermics | Initiates: Buy | $75 | $56.69 | +32.30% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $20.54 | +201.85% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $253.38 | +46.42% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $101.67 | +16.06% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $14.09 | +198.08% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $75.26 | +60.78% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $39.16 | +14.91% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $6.80 | +135.29% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $528.97 | +6.62% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.09 | +358.72% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.83 | +1,956.37% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $28.45 | +26.54% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $45.50 | +18.68% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $6.99 | -14.16% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.41 | +325.53% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.18 | +120.13% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $12.24 | +112.42% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.43 | +232.15% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.74 | +87.17% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $59.54 | +49.48% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $9.72 | +157.20% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $15.23 | +169.21% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $23.46 | +49.19% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $54.17 | +138.16% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $97.95 | -0.97% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $34.13 | +222.30% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.47 | +908.65% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.25 | +176.92% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $21.20 | +890.80% | 1 | Sep 2, 2020 |
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $8 → $16
Current: $4.83
Upside: +231.26%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $56.69
Upside: +32.30%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $20.54
Upside: +201.85%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $253.38
Upside: +46.42%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $101.67
Upside: +16.06%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $14.09
Upside: +198.08%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $75.26
Upside: +60.78%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $39.16
Upside: +14.91%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $6.80
Upside: +135.29%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $528.97
Upside: +6.62%
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.09
Upside: +358.72%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.83
Upside: +1,956.37%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $28.45
Upside: +26.54%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $45.50
Upside: +18.68%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $6.99
Upside: -14.16%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.41
Upside: +325.53%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.18
Upside: +120.13%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $12.24
Upside: +112.42%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.43
Upside: +232.15%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.74
Upside: +87.17%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $59.54
Upside: +49.48%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $9.72
Upside: +157.20%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $15.23
Upside: +169.21%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $23.46
Upside: +49.19%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $54.17
Upside: +138.16%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $97.95
Upside: -0.97%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $34.13
Upside: +222.30%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.47
Upside: +908.65%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $3.25
Upside: +176.92%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $21.20
Upside: +890.80%